Details

Analiza stroškov selitve proizvodnje izbranega podjetja : zaključna strokovna naloga visoke poslovne šole
ID Bizjak, Patricija (Author), ID Hočevar, Marko (Mentor) More about this mentor... This link opens in a new window

URLURL - Presentation file, Visit http://www.cek.ef.uni-lj.si/vps_diplome/bizjak1969.pdf This link opens in a new window

Language:Slovenian
Keywords:računovodstvo, stroški, kalkulacije, produkcija, primeri, Intra Lighting
Work type:Final paper
Typology:2.11 - Undergraduate Thesis
Organization:EF - School of Economics and Business
Place of publishing:Ljubljana
Publisher:[P. Bizjak]
Year:2021
Number of pages:II, 22 str.
PID:20.500.12556/RUL-133509 This link opens in a new window
UDC:338.5
COBISS.SI-ID:83763459 This link opens in a new window
Publication date in RUL:17.12.2021
Views:978
Downloads:91
Metadata:XML DC-XML DC-RDF
:
BIZJAK, Patricija, 2021, Analiza stroškov selitve proizvodnje izbranega podjetja : zaključna strokovna naloga visoke poslovne šole [online]. Bachelor’s thesis. Ljubljana : P. Bizjak. [Accessed 17 April 2025]. Retrieved from: http://www.cek.ef.uni-lj.si/vps_diplome/bizjak1969.pdf
Copy citation
Share:Bookmark and Share

Secondary language

Language:English
Title:The analysis of production relocation expenses in the selected company
Keywords:accounting, costs, calculations, production, cases, Intra Lighting

Similar documents

Similar works from RUL:
  1. ǂThe ǂrole of loyalty cards for consumers
  2. The impact of inflation on consumer behavior of millennials
  3. ǂThe ǂrole of the Instagram social medium in consumer buying behavior
  4. Odnos porabnikov do subliminalnega oglaševanja in vpliv subliminalnih sporočil na nakupno odločitev
  5. Sustainable orientation of consumers when purchasing apparel
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back